STOCK MARKET BSE NSE

Centre fails to finalise COVID vaccination details ahead of next phase of inoculation

Most of the states said they did not know how many vaccine doses—or which one—will they receive as the vaccination opens up for people above 60 years and over 45 with specific comorbidities.

Published: 28th February 2021 07:46 AM  |   Last Updated: 28th February 2021 07:47 AM   |  A+A-

A medic collects swab sample for Covid testing in Amritsar on Saturday. (Photo | PTI)

A medic collects swab sample for Covid testing in Amritsar on Saturday. (Photo | PTI)

Express News Service

NEW DELHI:  Just a day before the ongoing Covid-19 vaccination drive is set to be scaled up to cover those identified as one of the most vulnerable population groups, states are still in the blinds even on basic details as the Centre scrambled to finalise specifics at the last minute.

Most of the states on Saturday for instance said they did not know how many vaccine doses—or which one—will they receive as the vaccination opens up for people above 60 years and over 45 with specified comorbidities from Monday.

The cumulative number of this group is estimated to be nearly 12 crores—of which about 11 crores are people older than 60 years.

ALSO READ | COVID-19 vaccine to cost Rs 250 per dose in private hospitals, only Covishield to be available

Ministry of health and family welfare officials meanwhile said that after pricing negotiation with the companies—Serum Institute of India and Bharat Biotech—that continued for several rounds, talks are on to gauge the available stock of vaccine vials that can be immediately dispatched to states.

“While the number of the targeted group in every state is clearly estimated—we need to understand the stock availability with the companies and then distribute it to states accordingly,” said a government source. Sources also added that while the government has fixed a price of Rs 150 per dose for vaccine makers in private hospitals, manufacturers are not happy.

“The issue during the price negotiation was that how can the price of the vaccine in private hospitals be lower than the rate at which the Central government had procured it earlier for the first phase of vaccination,” an official told this newspaper.

“The companies were very reluctant in accepting the price.” Officials in few states meanwhile said that for the  expansion of the vaccination drive, while the states needed additional doses at least a day before, there is no clarity on when and how much will arrive. “We do not want a situation where entitled beneficiaries queue up for vaccines at a health facility and we have to tell them that enough vaccines are not available,” said a health department official in West Bengal.



Comments(1)

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

  • zishan

    #KiranMazumdarShaw SHOULD NOT CRY ON #COVID19VACCINE price CAP!! isnt it Biocon? its a fact that pharma's invest millions developing say eg: 10 product of which 1 make it to market and rest are rejected due to short-comings during #clinicaltrials ...pricing is done based on how much was invested in the drug making and how much investment was done behind ones that did not make it to market..FINAL PRICING IS DONE to compensate for the loss incurred during research of the 9 products that dint make into market!!...BUT SOME TIMES in emergency situations like this #COVID19 pandemic THESE PHARMAS ALSO NEED TO SHOULDER some economic burden!!
    1 month ago reply
flipboard facebook twitter whatsapp